Translating the biology of aging into novel therapeutics for Alzheimer disease

Yuko Hara, Nicholas McKeehan, Howard M. Fillit

Research output: Contribution to journalReview articlepeer-review

86 Scopus citations

Abstract

Aging is the leading risk factor for most chronic illnesses of old age, including Alzheimer disease (AD), a progressive neurodegenerative disease with currently no therapies that prevent, slow, or halt disease progression. Like other chronic diseases of old age, the progressive pathology of AD begins decades before the onset of symptoms. Many decades of research in biological gerontology have revealed common processes that are relevant to understanding why the aging brain is vulnerable to AD. In this review, we frame the development of novel therapeutics for AD in the context of biological gerontology. The many therapies currently in development based on biological gerontology principles provide promise for the development of a new generation of therapeutics to prevent and treat AD.

Original languageEnglish
Pages (from-to)84-93
Number of pages10
JournalNeurology
Volume92
Issue number2
DOIs
StatePublished - 8 Jan 2019
Externally publishedYes

Fingerprint

Dive into the research topics of 'Translating the biology of aging into novel therapeutics for Alzheimer disease'. Together they form a unique fingerprint.

Cite this